- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04401150
Lessening Organ Dysfunction With VITamin C - COVID-19 (LOVIT-COVID)
Lessening Organ Dysfunction With VITamin C - COVID
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background. Research suggests that vitamin C is potentially lifesaving in the intense inflammatory cascade such as that associated with COVID-19. Inflammation and oxidative stress are among the main mechanisms underlying COVID-19-associated acute hypoxemic respiratory failure. Previous evidence had also already established that a dysregulated inflammatory cascade may distinguish patients who transition from a relatively mild viral pneumonitis to acute respiratory distress syndrome and multiorgan failure. As such, adjunct immune modulation therapies may improve outcomes of COVID-19 patients who are hospitalized. Numerous preclinical studies have shown that, in addition to direct scavenging of oxygen radicals, vitamin C limits their production and restores endothelial function.
As the majority of hospitalized patients with COVID-19 are not critically ill, avoiding clinical deterioration and subsequent intensive care unit admission is a high priority. Participation in research should be offered before patients become critically ill, at which time many perceive that treatment may be too late. It is important to ensure that as many COVID-19 patients as possible are offered the opportunity to participate to research since that is generally the only means to access investigational therapies. The proposed trial will address this gap, by evaluating the efficacy of intravenous vitamin C in hospitalized patients with confirmed COVID-19.
Objectives. The overarching objective, which is identical to the objective of the parent LOVIT trial (NCT 03680274), is to determine whether intravenous vitamin C, compared to placebo, reduces morbidity and mortality in patients hospitalized with COVID-19. To ascertain the volume of distribution, clearance, and plasma concentration over a course of 96 hours of intravenous vitamin C 50 mg/kg of weight every 6 hours or matching placebo (pharmacokinetic (PK) substudy).
Methods. Patients will be randomly assigned to vitamin C (intravenous, 50 mg/kg every 6h) or placebo (0.9% NaCl or dextrose 5% in water) for 96 hours. Study personnel at the clinical sites will document the composite of death or persistent organ dysfunction at day 28. Daily assessments will occur for organ function, on days 1, 3, 7 for inflammation, infection, and endothelial injury biomarkers, at baseline for vitamin C level, and at 6 months for mortality and HRQoL. The LOVIT-COVID Trial will be conducted in Canadian and possibly international sites. For the PK substudy: Blood samples will be drawn around the 8th dose at time 0 and then after administration at times 1h, 2h, 4h and 6h (the 6h level will be immediately prior to the next dose). The PK substudy will be conducted with 100 participants in some of the participating centers.
Relevance. A growing body of evidence suggests that vitamin C, an inexpensive and readily available intervention, is potentially lifesaving in sepsis and may also be beneficial in COVID-19. LOVIT-COVID will constitute rigorous assessments of the effect of vitamin C monotherapy on patient-important outcomes. If proven effective, vitamin C could be used worldwide and drastically change outcomes in high- and low-income settings alike.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Center of the CHUS
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Research Centre of the CHUS
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Confirmed diagnosis of COVID-19;
- Admitted to hospital (ward or intensive care unit).
Exclusion Criteria:
- Receiving or has received vasopressors during the current hospitalization;
- More than 24 hours has elapsed since receipt of non-invasive ventilatory support (high-flow nasal cannula or continuous positive airway pressure or non-invasive ventilation) or invasive mechanical ventilation;
- Patient is expected to be discharged from the hospital in the next 24 hours;
- More than 14 days have elapsed since the commencement of hospital admission with respiratory illness;
- Known glucose-6-phosphate dehydrogenase (G6PD) deficiency;
- Known sickle cell anemia
- Pregnancy or breastfeeding;
- Known allergy to vitamin C;
- Known kidney stones within the past 1 year;
- Received any intravenous vitamin C during this hospitalization unless incorporated in parenteral nutrition;
- Expected death or withdrawal of life-sustaining treatments within 48 hours;
- Previously enrolled in this study;
- Previously enrolled in a trial for which co-enrolment is not allowed (co- enrolment to be determined case by case).
The trial has broad eligibility criteria and includes all COVID-19 patients admitted to the hospital (e.g. hospital ward or the intensive care unit) who are not receiving vasopressors.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin C
Vitamin C: 50 mg/kg of weight administered intravenously every 6 hours for 96 hours (16 doses).
|
Intravenous vitamin C administered in bolus doses of 50 mg/kg mixed in a 50-ml solution of either normal saline (0.9% NaCl) or dextrose 5% in water (D5W) during 30 to 60 minutes, every 6 hours for 96 hours (i.e.
200 mg/kg/day and 16 doses in total).
Other Names:
|
Placebo Comparator: Control
Normal saline (0.9% NaCl) or dextrose 5% in water (D5W) in a volume to match the vitamin C.
|
Dextrose 5% in water of normal saline (0.9% NaCL) in a volume to match vitamin C.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Death or persistent organ dysfunction
Time Frame: Both assessed at 28 days
|
Number of deceased participants or with persistant organ dysfunction (dependency on mechanical ventilation, new renal replacement therapy, or vasopressors).
|
Both assessed at 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of intensive care unit-free days
Time Frame: Assessed at 21 days
|
Number of whole and part study days for which the patient is alive and not admitted to an intensive care unit
|
Assessed at 21 days
|
Persistent organ dysfunction-free days in ICU
Time Frame: Assessed at 28 days
|
Number of study days in ICU without persistant organ dysfunction
|
Assessed at 28 days
|
Number of patients deceased at 6 months
Time Frame: 6 months
|
Mortality at 6 months
|
6 months
|
Health related quality of life in 6-month survivors
Time Frame: 6 months
|
Assessed by the EQ-5D-5L EuroQol questionnaire (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ-5D visual analog scale (EQ VAS). The descriptive system comprises 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The patient is asked to indicate her/his health state by ticking the box next to the most appropriate statement in each of the 5 dimension. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number that describes the patient's health state. The EQ-VAS records the patient's self-rated health on a vertical visual analog scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. |
6 months
|
Organ function
Time Frame: Days 1, 2, 3, 4, 7, 10, 14, 28
|
Assessed by the Sequential Organ Failure Assessment (SOFA) score.
Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure.
The score is based on six different sub-scores, one each for the respiratory (PaO2/fraction of inspired oxygen FiO2) mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin mg/dl [µmol/L]), coagulation (platelets x 103/µl), renal (kidneys creatinine (mg/dl) [µmol/L] (or urine output)), and neurological (Glasgow coma scale).
The sub-score of each system ranges from 0 (best) to +4 (worst).
|
Days 1, 2, 3, 4, 7, 10, 14, 28
|
Global tissue dysoxia
Time Frame: Days 1, 3, 7
|
Assessed by serum lactate concentration
|
Days 1, 3, 7
|
Rate of inflammation
Time Frame: Days 1, 3, 7
|
Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP).
|
Days 1, 3, 7
|
Rate of infection
Time Frame: Days 1, 3, 7
|
Assessed by procalcitonin (PCT).
|
Days 1, 3, 7
|
Rate of endothelial injury
Time Frame: Days 1, 3, 7
|
Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2).
|
Days 1, 3, 7
|
Occurrence of stage 3 acute kidney injury
Time Frame: Up to day 28
|
Assessed by Kidney Disease: Improving Global Outcomes (KDIGO) criteria
|
Up to day 28
|
Acute hemolysis
Time Frame: Up to day 28
|
Severe hemolysis: o hemoglobin <75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells. |
Up to day 28
|
Hypoglycemia
Time Frame: During the time participants receive the 16 doses of the investigational product and the 7 days following the last dose.
|
Core lab-validated glucose level <3.8 mmol/L
|
During the time participants receive the 16 doses of the investigational product and the 7 days following the last dose.
|
Vitamin C volume of distribution
Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Assessed by chromatography-tandem mass spectrometry
|
8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Vitamin C clearance
Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Assessed by chromatography-tandem mass spectrometry
|
8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Vitamin C plasma concentration
Time Frame: 8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Assessed by chromatography-tandem mass spectrometry
|
8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy).
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: François Lamontagne, MD, FRCPC, MSc, Université de Sherbrooke and CIUSSS de l'Estrie - CHUS
- Principal Investigator: Neill K Adhikari, MDCM, FRCPC, MSc, Sunnybrook Health Sciences Centre, University of Toronto
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Protective Agents
- Micronutrients
- Vitamins
- Antioxidants
- Ascorbic Acid
Other Study ID Numbers
- MP-31-2021-3741
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
Clinical Trials on Vitamin C
-
Shiraz University of Medical SciencesCompletedRestless Legs Syndrome | Kidney Failure, ChronicIran, Islamic Republic of
-
AronPharma Sp. z o. o.Medical University of Warsaw; Medical University of GdanskCompletedBioavailability of Vitamin CPoland
-
TCI Co., Ltd.CompletedVitamin C DeficiencyTaiwan
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)TerminatedClear Cell Renal Cell Carcinoma | Metastatic Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Unresectable Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v7United States
-
Fudan UniversityRecruitingMetastatic Pancreatic Cancer | Terminal CancerChina
-
University of East AngliaThe Norfolk and Norwich University Hospitals NHS Foundation Trust; The Quadram...Not yet recruiting
-
Damascus UniversityRecruitingDistal Radius Fracture | Prophylaxis | Vitamine cSyrian Arab Republic
-
CargillClinres Farmacija d.o.o.; PharmaLinea d.o.o.; Diagnostic Laboratory Medicare... and other collaboratorsCompletedSigns and Symptoms, RespiratorySlovenia
-
Austin Institute for Clinical ResearchSkinCeuticalsNot yet recruiting